CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
IVT Aflibercept +1 moredrug
Likely dose
IVT Aflibercept 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02949024
NCT02949024Phase 2Completed
CompareCT.gov

Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema

Clearside Biomedical, Inc.·interventional·Posted Oct 31, 2016·Updated May 13, 2021

In Brief

A Phase 2 clinical trial evaluating IVT Aflibercept and SC CLS-TA for Diabetic Macular Edema. Completed, enrolled 20 participants across 2 sites.

Detailed Summary

This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 31, 2016
Enrollment StartNov 10, 2016
Primary CompletionOct 17, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.7 years ago

Interventions

IVT Afliberceptdrug

IVT aflibercept \[2 mg (50 µL)\]

SC CLS-TAdrug

\[4 mg (100 µL)\]